Background: Postmenopausal hormone therapy may have long-term effects on cognitive function depending on women's age. Methods: Postintervention follow-up was conducted with annual cognitive assessments of two randomized controlled clinical trial cohorts, beginning an average of 6-7 years after study medications were terminated: 1,376 women who had enrolled in the Women's Health Initiative when aged 50-54 years and 2,880 who had enrolled when aged 65-79 years. Women had been randomly assigned to 0.625 mg/d conjugated equine estrogens (CEE) for those with prior hysterectomy (mean 7.1 years), CEE with 2.5 mg/d medroxyprogesterone acetate for those without prior hysterectomy (mean 5.4 years), or matching placebos. Results: Hormone therapy, when prescribed to women aged 50-54 years, had no significant long-term posttreatment effects on cognitive function and on changes in cognitive function. When prescribed to older women, it was associated with long-term mean (SE) relative decrements (standard deviation units) in global cognitive function of 0.081 (0.029), working memory of 0.070 (0.025), and executive function of 0.054 (0.023), all p < .05. These decrements were relatively stable over time. Findings did not vary depending on the hormone therapy regimen, prior use, or years from last menstrual period. Mean intervention effects were small; however, the largest were comparable in magnitude to those seen during the trial's active intervention phase. Conclusions: CEE-based hormone therapy delivered near the time of menopause provides neither cognitive benefit nor detriment. If administered in older women, it results in small decrements in several cognitive domains that remain for many years.
In older women, cognitive deficits related to hormone therapy emerge within the first few years (1, 2) and persist several years after medications are terminated (3) . The increased risk for cognitive impairment associated with these deficits appears to be directly linked to changes in brain volume, in particular hippocampal atrophy (4) .
When administered to women within a few years of menopause, however, hormone therapy appears to have little overall effect on cognitive function. Evidence for this comes from the Women's Health Initiative Memory Study of Younger Women (WHIMSY) volunteers, who were enrolled when aged 50-54 years in the Women's Health Initiative randomized controlled clinical trials of hormone therapy and followed for an average of 7 years (5). When these women's cognitive function was assessed 5 years following the termination of the trials, no significant treatment effects were observed (6) . Subsequently, the Kronos Early Estrogen Prevention Study (KEEPS) randomized clinical trial also reported no cognitive treatment effects from 4 years of hormone therapy among women enrolled more proximal to the menopausal transition (7) . These null effects are reassuring for the millions of women who use hormone therapy near the menopausal transition to manage its symptoms.
In women 65 years and older, hormone therapy results in relative decrements in brain volumes that remain evident years after treatment is terminated (8, 9) . In other settings, cognitive deficits may become manifest only years after initial alterations in brain structure (10); therefore, further assessment with longer-term follow-up is important to evaluate safety in younger women.
We report findings from extended follow-up of the WHIMSY cohort, assessing cognitive data from up to six annual assessments. We are interested in two main questions. Are there differences in mean cognitive function between intervention and placebo groups that emerge with longer follow-up? Does there appear to be differences in the relative rates of change in cognitive function between intervention and placebo groups? Our goal is to understand whether any late effects of hormone therapy are evident. We also draw data from the Women's Health Initiative Memory Study of the Epidemiology of Cognitive Health Outcomes (WHIMS-ECHO), which paralleled the WHIMSY follow-up in an older cohort of women who were originally aged 65-79 years when enrolled in the WHI hormone therapy trials. This allows us to contrast the long-term relative effects of random assignment to 4-6 years of hormone therapy on younger versus older women. We examine whether findings vary depending on regimen (ie, unopposed vs opposed therapy), prior use of hormone therapy, and duration between time of menopause and WHI enrollment. Because we recently reported that the effect of hormone therapy on cognitive function in older women varies depending on diabetes (11), we also examine the consistency of findings among women grouped by diabetes.
Methods
The Women's Health Initiative hormone therapy trials assessed two conjugated equine estrogens (CEE) regimens among postmenopausal women who were appropriate candidates for these therapies (12) . If they were currently using hormone therapy, they underwent a 3-month washout period prior to randomization. Enrollment occurred from 1996 to 1999 at 40 academic research centers. Active therapies consisted of 0.625 mg/d CEE in women posthysterectomy and 0.625 mg/d CEE combined with 2.5 mg/d medroxyprogesterone acetate (MPA) in women without hysterectomy. Both regimens were compared with matching placebos. The trial among women without prior hysterectomy (CEE + MPA) was terminated in July 2002; the trial among women with prior hysterectomy (CEE-Alone) was terminated in February 2004. Study medications were stopped at these times and women were unmasked, but continued to be followed annually. The intervention phases of these trials for women included in our analyses averaged (range) 5.4 (3.8-8.6) years and 7.1 (5.4-10.1) years, respectively. Supplementary Exhibit A is a schematic of the timeline for these trials.
WHIMSY volunteers had enrolled in the Women's Health Initiative hormone therapy trials when they were aged 50-54 years (5) . To be eligible for WHIMSY, they were required to be currently engaged in WHI follow-up, provide informed consent to undergo annual telephone-based assessments of their cognitive function, allow a friend or family member to be contacted, and to have hearing acuity adequate for telephone interviews. WHIMS-ECHO volunteers had enrolled in the Women's Health Initiative hormone therapy trials when they were aged 65-79 years and had received clinic-based cognitive testing through 2007 as part of the Women's Health Initiative Memory Study (WHIMS) (13) and its extension. Except for age, WHIMS-ECHO eligibility criteria were the same as for WHIMSY. All women provided written informed consent and all protocols were approved by local Institutional Review Boards.
Cognitive Measures
In 2008, a common protocol for telephone-based cognitive assessment was begun in the WHIMSY and WHIMS-ECHO cohorts (5), which has been validated independently (14) . We describe data collected through July 2015, when the WHIMSY surveillance was terminated according to protocol and participants had been scheduled to complete five or six planned assessments, depending on the date of their enrollment. Annual centralized telephone-administered cognitive interviews were conducted by trained and certified staff to collect the following measures:
The Telephone Interview for Cognitive Status-modified (TICS-m) is a widely used measure of global cognitive functioning (15) . It is a 14-question test (range of scores 0-50); higher scores reflect better performance.
The East Boston Memory Test (EBMT) measures verbal memory. Participants are read a short paragraph consisting of 12 distinct elements and immediately asked to recall as many elements as possible (immediate recall) and again 15 minutes later (delayed recall), with higher scores reflecting better performance (16) .
The Oral Trail Making Test (OTMT) is a modified version of the original Trail Making Test, a widely used and well-validated measure of attention (Part A) and executive function (Part B) (17) . Scores are the time (seconds) to complete the tasks, so that higher scores reflect poorer performance. Participants who do not complete these tests in the allotted maximum of 300 seconds are assigned scores of 300. This affected only two OTMT-A tests. Within WHIMSY, 4.9% of women who had been assigned to hormone therapy and 4.9% of the women who had been assigned to placebo had at least one incomplete OTMT-B test. In WHIMS-ECHO, these rates were 17.3% and 15.6% and increased during follow-up as women aged.
The Verbal Fluency-Animals (VF-A) test, a measure of semantic verbal fluency, requires participants to spontaneously name as many animals as possible during 1 minute (18) . The total number of unique words is the score, with higher scores reflecting better performance.
The Digit Span Test (DST) measures working memory (19) . Participants repeat a series of single digit numbers of increasing length that were presented orally, first as presented (DST forward) and subsequently in reverse order (DST backward). The score is the number of correctly recalled digit spans, with higher scores reflecting better performance.
Covariates and Potential Confounders
The WHI collected baseline demographic, lifestyle, and clinical data related to the risk of cognitive impairment via self-report and standardized assessments (12) . These included age, education, race/ethnicity, body mass index, hypertension, treatment assignment, history of stroke, history of cardiovascular disease (myocardial infarction, angina, percutaneous transluminal coronary angioplasty, revascularization, coronary artery bypass graft surgery, or stroke), diabetes, smoking, physical activity, and alcohol use. Time between WHI randomization and cognitive testing was calculated. Adherence was computed as the average proportion of assigned study medication used during the trial, based on pill counts. Years of on-trial exposure were computed by summing each woman's adherence rates (based on pill counts) across her years of trial follow-up. WHIMS-ECHO women had received annual cognitive testing prior to WHIMS-ECHO with the Modified Mini-Mental State Exam (3MSE) (20) , a 100-point test of global cognitive functioning, with higher scores reflecting better performance.
Statistical Methods
Characteristics of the cohorts and intervention groups were compared using chi-square tests and analyses of variance. General linear models (21) with contrast statements and covariate adjustments were used to assess differences in cognitive function scores (individual tests and a composite based on averaging normalized scores across tests) and relative differences in rates of change in cognitive function scores over time between treatment groups (hormone therapy vs placebo) for the two cohorts. We expressed mean differences between treatment groups in the units of each test and, to facilitate comparisons among cognitive tests, in units based on the standard deviations (SD) of cohorts at their initial assessment. The distributions of the OTMT-A and OTMT-B test scores were highly right skewed. We used winsorization (5% for Part A and 10% for Part B, with cutpoints drawn from the distribution of scores at baseline across both study groups) to limit the influence of extreme values (22) . A composite score was calculated by averaging standardized scores of the individual tests (ordered so that higher scores reflected better performance). Subgroup analyses were designed to test interactions for women grouped by hysterectomy status, prior use of hormone therapy, diabetes, and (in WHIMSY) years since last menstrual period.
Inverse probability weighting and multiple imputation methods were used to gauge the sensitivity of findings (both in inference an estimation bias) to the possibility of differential enrollment and follow-up in WHIMSY and WHIMS-ECHO. To accomplish this, we used the following characteristics at WHI enrollment: age, geographical region, education, race/ethnicity, smoking status, body mass index, waist hip ratio, hypertension, systolic and diastolic blood pressure, history of cardiovascular disease, diabetes, history of depression, prior hysterectomy, prior use of hormone therapy, and clinic site. For WHIMS women, we also included baseline 3MSE score. For this analysis, any missing characteristics were imputed (23) and logistic regression was used to compute probabilities that these women were enrolled in WHIMSY and WHIMS-ECHO.
Results
As seen in Table 1 , the WHIMSY (N = 1,376) and WHIMS-ECHO (N = 2,880) cohorts differed with respect to many risk factors for cognitive decline, including age, education, race/ethnicity, smoking, and history of hysterectomy, cardiovascular disease, and diabetes (all p < .05). The WHIMS-ECHO cohort was also more likely to have used hormone therapy in the past. Importantly, the balance between intervention groups with respect to these risk factors promoted by the original randomization was maintained in these cohorts (all p > .10). WHIMSY women tended to have longer on-trial exposure than WHIMS-ECHO women because WHIMS enrollment started later. WHIMSY cognitive assessments were initiated a mean of 7.2 years after the trials had ended, compared to 6.4 years for WHIMS-ECHO participants.
No cognitive assessments of the WHIMSY cohort were conducted during the WHI trials, but the WHIMS cohort received annual 3MSE testing. As seen in Table 1 , among the subset of women from the original WHIMS cohort that were followed in WHIMS-ECHO, baseline 3MSE scores were slightly, but not significantly, higher among women who had been assigned to hormone therapy. As seen in Supplementary Exhibit B, these small nonsignificant differences had been maintained for several years during WHIMS follow-up.
During WHIMSY, the number of annual interviews conducted during the study timeframe at years 1-6 was 1,264, 1,174, 1,051, 977, 935, and 586, respectively. During WHIMS-ECHO, the number of annual interviews conducted at years 1-7 was 2,880, 2,570, 2,236, 1,956, 1,654, 1,279, and 627, respectively. The mean number of assessments did not differ between intervention groups (Table 1 ; p = .68). As seen in Table 2 , there were no marked differences in the mean levels of cognitive function scores over follow-up between intervention groups in WHIMSY (all p ≥ .20), after covariate adjustment for age at enrollment, education, race/ethnicity, and hysterectomy history. In WHIMS-ECHO, the placebo group had significantly (p < .05) better mean performances of the TICS-m global cognitive function scores (p = .01; mean difference 0.071 SD), the OTMT-Part B (p = .02; mean difference 0.054 SD), and the DST forward (p = .008; mean difference 0.068 SD). Also included in Table 2 are the relative differences in progression rates (hormone therapy minus placebo) for the cognitive function tests. In WHIMSY, these were relatively small and mixed (p ≥ .10). In WHIMS-ECHO, differences in relative progression rates were also relatively small (p ≥ .09). Figures 1A and B portray the trajectories for the TICS-m and composite cognitive function mean scores. Note that trajectories of mean performance increase with time, reflecting learning effects and potentially differential follow-up: Our analytical approach accounts for any systematic effects over time between groups in comparing relative differences in slopes.
We used tests of interactions to examine whether there were any differences between intervention groups for the composite cognitive function measure based on baseline hysterectomy (which defines CEEAlone vs CEE + MPA therapy), prior use of hormone therapy, and years since last menstrual period. None reached statistical significance (Table 3) . Also, there were no significant differences in the relative rates of changes over time between intervention groups. We also examined whether intervention differences varied by diabetes status: No differences were seen for the composite cognitive function measure.
Women enrolled in WHIMSY differed from other women who had enrolled in the WHI hormone therapy trials when aged 50-54 years with respect to many factors (p < .05): They had lower rates of prior hysterectomy, greater rates of prior hormone therapy use, were less likely to be from a racial/ethnic minority, were more highly educated, reported greater family incomes and more alcohol use, and were less likely to have a history of diabetes or hypertension. They also had fewer symptoms of depression, lower mean body mass index, and lower blood pressures. They did not differ in rates of prior cardiovascular disease and smoking history.
In similar fashion, women enrolled in WHIMS-ECHO differed from other WHIMS women with respect to many factors (p < .05): They were younger, had lower rates of prior hysterectomy, were less likely to be from a racial/ethnic minority, were more highly educated, reported greater family incomes and more alcohol use, and were less likely to have a history of diabetes, cardiovascular disease, or hypertension. They also had lower mean systolic blood pressure and higher 3MSE scores at WHIMS baseline. They did not differ according to a measure of depressive symptoms or mean diastolic blood pressure.
We applied inverse probability weighting to assess the impact of this differential enrollment on estimates of intervention group differences. Supplementary Exhibit C portrays the results of these analyses. In general, means from these analyses reflect poorer performance on cognitive testing compared with the results unweighted results in Table 2 . This is due to lower rates of WHIMSY and WHIMS-ECHO enrollment among WHI women who had greater burdens of risk factors for cognitive deficits. Overall, however, the estimated treatment effects from these analyses are very similar to those from the unweighted analyses.
Pill counts were obtained annually on WHI participants in the hormone therapy trials, and rates (percentages of expected) were obtained. We summed these over follow-up to estimate adherence/ exposure: For example, a woman with an 80% pill count for a year would accrue 0.8 years of exposure. For the WHIMSY women, the means were 5.52 (hormone therapy) and 5.36 (placebo) years of exposure (p = .16). For the WHIMS-ECHO women, these were 4.29 (hormone therapy) and 4.76 (placebo) years of exposure (p < .001). There were no significant (p < .05) interactions between this marker of adherence/exposure and treatment assignment on any measure of cognitive function. The most marked was among WHIMS-ECHO women for the test of verbal fluency, with fitted slopes between scores and exposure of −0.013 (0.012) SD per year among women who had been assigned to hormone therapy and 0.019 (0.012) SD per year among women who had been assigned to placebo (interaction p = .06). Among the WHIMSY women, 7.8% of the women who had been assigned to hormone therapy and 12.1% who had been assigned to placebo reported use of estrogen medications, for any reason, at some time following the termination of study medications. For WHIMS-ECHO women, these rates were 2.3% and 3.6%, respectively. In neither study was post-trial estrogen use associated with mean levels of cognitive function (p = .42 and p = .95, respectively).
Discussion
For the women in WHIMSY, consistent with our earlier report based on the first 2 years of follow-up (6), we found little evidence that the administration CEE-based hormone therapy to postmenopausal women aged 50-54 years resulted in any long-term relative decrements in cognitive function, and no evidence of benefit. The sample size and follow-up provided sufficient power (>90%) to detect mean intervention differences as small as 0.10 SD for the composite cognitive outcome; thus, persistent treatment effects of this magnitude can be ruled out with a high degree of certainty.
For the older women in WHIMS and WHIMS-ECHO, there appeared to be a small but persistent relative decrement in markers of working memory, executive function, and global cognitive function. Although the relative rates of cognitive decline in WHIMS-ECHO were all estimated to be greater among hormone therapy women compared to placebo, none reached nominal (p < .05) levels of statistical significance so that there appeared to be no lingering acceleration of cognitive aging.
Long-term Effects of Hormone Therapy
During the intervention phase of the WHI hormone therapy trials, women aged 65-79 years assigned to hormone therapy had statistically significant (p < .05) relative decrements in measures of global cognitive functioning, verbal knowledge, and verbal fluency, with mean treatment-related decrements ranging from 0.07 to 0.08 SD. There also were marginally significant (p < .10) treatment-related decrements in figural memory, working memory, and fine motor speed ranging from 0.06 to 0.07 SD (1) (2) (3) . During the 4-5 years following the cessation of study therapy, mean treatment-related decrements in these women tended to attenuate, but remained 0.07 SD (p = 0.01) for global cognitive function (3). Subsequent to this, in WHIMS-ECHO, interventionassociated mean decrements were seen for global cognitive function and working memory of 0.07 and 0.05 SD units for executive function.
Cognitive function was not assessed during the intervention phase of the WHI hormone therapy trials among younger postmenopausal women, but it is likely, given the results from the KEEPS study (7) , that there were no measureable intervention effects. No overall intervention effects were seen during WHIMSY, as well. The largest treatmentassociated mean decrement in WHIMSY averaged less than 0.05 SD. If there were underlying effects on brain structure in these women, we conclude that they had not produced meaningful cognitive deficits.
There is considerable evidence that the influences estrogen has on brain health and brain function vary with age (24, 25) and potentially with age-related diseases (11, 26, 27) . The findings we report suggest that as women age beyond menopause, at some point hormone therapy adversely affects cognitive function. A potential mechanism that may account for this transition is related to estrogen's role in regulating energy metabolism in the brain by promoting glucose-based energy utilization through increased glucose transport and aerobic glycolysis (28) . As the postmenopausal brain adapts to loss of estrogen, secondary energy sources such as ketones and fatty acids may become more important over time (29) . Reintroducing higher levels of estradiol through hormone therapy later in life, downregulates the metabolism of these energy sources, which may disrupt cognitive function. Other mechanisms are possible. Age and age-related chronic diseases change the expression of estrogen receptor-alpha and estrogen receptor-beta in the brain and how estrogen receptor-alpha responds to estrogen (30) (31) (32) , which may contribute to differential effects of hormone therapy on cognition between the two cohorts. We have previously reported that the adverse impact of hormone therapy on cognitive function in the WHIMS cohort was strongest among women with lower baseline levels (2): Differences in the levels of education and the prevalence of risk factors for cognitive decline (hypertension, diabetes, cardiovascular disease) between the two cohorts may also contribute to differential hormone therapy effects. We saw no overall differences between CEE-Alone and CEE + MPA therapy and between women who had and had not used hormone therapy prior to enrolling in the WHI. We also did not see differences in intervention effects among WHIMSY women grouped by years since menopause onset. If these factors influence intervention effects, our data suggest that these influences are minor.
Limitations
The data we analyzed came from volunteers for a clinical trial, and thus may not represent general populations. The mean effects we describe are small, only being detectable with sample sizes of over 1,000 women, and power to detect differences in effects among subgroups of women was limited. Although there is likely variability in the effect sizes among women, those equal to the mean differences we report would not be meaningful for an individual woman. Even for the largest differences we report, the p values are relatively modest and would not reach statistical significance if type I error was controlled across the many inferences we report. Although we have, in supporting analyses, attempted to adjust for differential attrition occurring from WHI baseline until enrollment into the WHIMSY and WHIMS-ECHO studies, we cannot rule out unmeasured factors that may have contributed to this.
Summary
CEE-based hormone therapy appears to have no long-term effects on cognitive function when administered for up to 6 years in women aged 50-54 years. In contrast, administration of 5 years of hormone therapy to women aged 65-79 years results in small mean decrements in global cognitive function that persist for over a decade from the start of administration. 
